Pedro A. Torres‐Saavedra

Author

Also Known As

P. Torres-Saavedra, Pedro A Torres-Saavedra, Pedro A. Torres-Saavedra, Pedro A. Torres‐Saavedra, Pedro Torres-Saavedra, Wade Thorstad

Publications

1.2K

Citations

H-Index

Concepts

All Affiliations

NRG Oncology American College of Radiology Stanford University Moffitt Cancer Center The University of Texas MD Anderson Cancer Center

About

Pedro A. Torres‐Saavedra is an author at NRG Oncology specializing in oncology, medicine, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	9	403
2	Health Sciences	5	5	87
3	Head And Neck Surgery	2	2	23
4	Public Health	1	1	24
5	Epidemiology	1	1	24

Pedro A. Torres‐Saavedra

Publications

883

Citations

H-Index

Page 1

	Year	Citations
Reduced-Dose Radiation Therapy for HPV-Associated Oropharyngeal Carcinoma (NRG Oncology HN002) Sue S. Yom, Pedro A. Torres‐Saavedra, Jimmy J. Caudell, Journal of Clinical Oncology	2021	344
Chemotherapy and radiotherapy in locally advanced head and neck cancer: an individual patient data network meta-analysis Claire Petit, Benjamin Lacas, Jean‐Pierre Pignon, The Lancet Oncology Adaptive RadiotherapyAdvanced HeadNeck CancerMedicineHead And Neck Cancer	2021	100
Drugs and Alcohol: Their Relative Crash Risk Eduardo Romano, Pedro A. Torres‐Saavedra, Robert B. Voas, Journal of Studies on Alcohol and Drugs	2014	90
NRG-HN002: A Randomized Phase II Trial for Patients With p16-Positive, Non-Smoking-Associated, Locoregionally Advanced Oropharyngeal Cancer Sue S. Yom, Pedro A. Torres‐Saavedra, Jimmy J. Caudell, International Journal of Radiation OncologyBiologyPhysics MedicinePathologyCancer TreatmentOncologyRadiation Oncology	2019	87
Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2/3 trial Loren K. Mell, Pedro A. Torres‐Saavedra, Stuart J. Wong, The Lancet Oncology	2024	44
Pathologic Complete Response and Clinical Outcomes in Patients With Localized Soft Tissue Sarcoma Treated With Neoadjuvant Chemoradiotherapy or Radiotherapy Dian Wang, Jonathan Harris, William Kraybill, JAMA Oncology	2023	38
Radiotherapy and paclitaxel plus pazopanib or placebo in anaplastic thyroid cancer (NRG/RTOG 0912): a randomised, double-blind, placebo-controlled, multicentre, phase 2 trial Eric J. Sherman, Jonathan Harris, Keith C. Bible, The Lancet Oncology Radiation MedicineOncologyRadiation TherapyThyroid DiseaseNrg/rtog 0912	2023	37
Marijuana and the Risk of Fatal Car Crashes: What Can We Learn from FARS and NRS Data? Eduardo Romano, Pedro A. Torres‐Saavedra, Robert B. Voas, The Journal of Primary Prevention Cannabis UseSubstance AbuseSubstance UseNrs DataFatal Car Crashes	2017	24
Long-Term Update of NRG/RTOG 0522: A Randomized Phase 3 Trial of Concurrent Radiation and Cisplatin With or Without Cetuximab in Locoregionally Advanced Head and Neck Cancer Jimmy J. Caudell, Pedro A. Torres‐Saavedra, D.I. Rosenthal, International Journal of Radiation OncologyBiologyPhysics Radiation MedicineRadiation TherapyNrg/rtog 0522MedicineHead And Neck Cancer	2022	21
Alcohol-Related Risk of Driver Fatalities in Motor Vehicle Crashes: Comparing Data From 2007 and 2013–2014 Eduardo Romano, Pedro A. Torres‐Saavedra, Hilda I Calderon Cartagena, Journal of Studies on Alcohol and Drugs	2018	20

Page 1